Search bioRxiv⌕ Search

Biology subjects

Lerda, G.

Publications and source records attributed to Lerda, G..

2 recordsLinked to original sources

Chemotherapy reshapes cellular clonal landscape via persister programs in breast cancer xenografts

Tumor ecosystems evolve in response to chemotherapy, but how treatment reshapes clonal architecture and the transcriptional programs of distinct cell states remains unclear. To investigate the response to chemotherapy by individual single cell-derived clones, we used a high-complexity lentiviral barcoding strategy by genetically labelling with unique, heritable and expressible barcode sequences individual cells from four human breast cancer patient-derived tumor xenograft models. We tracked 3,248 single cell-derived clones across 39 xenografts and profiled 676,292 cells with single cell RNA sequencing. The most striking changes following chemotherapy occurred in non-responsive xenografts, attributed to the emergence of previously minor cell clones that are chemotherapy resistant. In a triple negative model, epithelial and mesenchymal cell states showed distinct sensitivities to chemotherapy. ER+/HER2-models activated stress adaptive programs in response to carboplatin, highlighting DUSP1 and KLF4 as markers of platinum tolerance and a slow cycling, persister-like state. Together, these findings reveal that chemotherapy triggers an immediate and substantial reorganization of the cellular clonal landscape, driven by the selective engagement of stress response programs in cell clones that survive treatment.

cancer biology↗

Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts

Triple negative breast cancers (TNBC) exhibit inter- and intra-tumour heterogeneity, which is reflected in diverse drug responses and interplays with tumour evolution. Here, we use TNBC patient-derived tumour xenografts (PDTX) as a platform for co-clinical trials to test their predictive value and explore the molecular features of drug response and resistance. Patients and their matched PDTX exhibited mirrored drug responses to neoadjuvant therapy in a clinical trial. In parallel, additional clinically-relevant treatments were tested in PDTXs in vivo to identify alternative effective therapies for each PDTX model. This framework establishes the foundation for anticipatory personalised therapies for those patients with resistant or relapsed tumours. The PDTXs were further explored to model PDTX- and treatment-specific behaviours. The dynamics of drug response were characterised at single-cell resolution revealing a novel mechanism of response to olaparib. Upon olaparib treatment PDTXs showed phenotypic plasticity, including transient activation of the immediate-early response and irreversible sequential phenotypic switches: from epithelial to epithelial-mesenchymal-hybrid states, and then to mesenchymal states. This molecular mechanism was exploited ex vivo by combining olaparib and salinomycin (an inhibitor of mesenchymal-transduced cells) to reveal synergistic effects. In summary, TNBC PDTXs have the potential to help design individualised treatment strategies derived from model-specific evolutionary insights.

cancer biology↗